ABEONA THERAPEUTICS INC. Operating Lease Cost
ABEONA THERAPEUTICS INC. (ABEO) reported Operating Lease Cost of $282.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. operating lease, cost for the quarter ending 2026-06-30 was $282.00K, a 25.79% decline year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, cost for the quarter ending 2026-03-31 was $281.00K, a 24.46% decline year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, cost for the quarter ending 2025-12-31 was $264.00K, a 15.92% decline year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, cost for the quarter ending 2025-09-30 was $385.00K, a 23.40% increase year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, cost for fiscal 2025 was $1.40M, a 8.77% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. operating lease, cost for fiscal 2024 was $1.29M, a 7.27% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. operating lease, cost for fiscal 2023 was $1.39M, a 25.52% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. operating lease, cost for fiscal 2022 was $1.86M, a 5.91% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $282.00K 10-Q · filed 2026-08-13 | $563.00K 10-Q · filed 2026-08-13 | $827.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.21M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $281.00K 10-Q · filed 2026-05-13 | $545.00K derived: sum of 2 quarters · filed 2026-05-13 | $930.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $649.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.03M derived: sum of 3 quarters · filed 2026-08-13 | $1.40M 10-K · filed 2026-03-17 |
| 2025-09-30 | $385.00K 10-Q · filed 2025-11-12 | $765.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.14M 10-Q · filed 2025-11-12 | $1.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $380.00K 10-Q · filed 2026-08-13 | $752.00K 10-Q · filed 2026-08-13 | $1.07M derived: sum of 3 quarters · filed 2026-08-13 | $1.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $372.00K 10-Q · filed 2026-05-13 | $686.00K derived: sum of 2 quarters · filed 2026-05-13 | $998.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.33M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $626.00K derived: sum of 2 quarters · filed 2026-03-17 | $954.00K derived: sum of 3 quarters · filed 2026-03-17 | $1.29M 10-K · filed 2026-03-17 |
| 2024-09-30 | $312.00K 10-Q · filed 2025-11-12 | $640.00K derived: sum of 2 quarters · filed 2025-11-12 | $974.00K 10-Q · filed 2025-11-12 | $1.31M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $328.00K 10-Q · filed 2025-08-14 | $662.00K 10-Q · filed 2025-08-14 | $1.00M derived: sum of 3 quarters · filed 2025-08-14 | $1.34M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $334.00K 10-Q · filed 2025-05-15 | $675.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.01M derived: sum of 3 quarters · filed 2025-05-15 | $1.37M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $341.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $681.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.03M derived: sum of 3 quarters · filed 2025-03-20 | $1.39M 10-K · filed 2025-03-20 |
| 2023-09-30 | $340.00K 10-Q · filed 2024-11-14 | $693.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.05M 10-Q · filed 2024-11-14 | $1.57M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $353.00K 10-Q · filed 2024-08-12 | $708.00K 10-Q · filed 2024-08-12 | $1.23M derived: sum of 3 quarters · filed 2024-08-12 | $1.70M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $415.00K 10-Q · filed 2024-05-15 | $880.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.35M derived: sum of 3 quarters · filed 2024-05-15 | $1.81M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $465.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $932.00K derived: sum of 2 quarters · filed 2024-03-18 | $1.39M derived: sum of 3 quarters · filed 2024-03-18 | $1.86M 10-K · filed 2024-03-18 |
| 2022-09-30 | $467.00K 10-Q · filed 2023-11-13 | $928.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.40M 10-Q · filed 2023-11-13 | $1.86M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $461.00K 10-Q · filed 2023-08-08 | $933.00K 10-Q · filed 2023-08-08 | $1.39M derived: sum of 3 quarters · filed 2023-08-08 | $1.83M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $472.00K 10-Q · filed 2023-05-11 | $931.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.36M derived: sum of 3 quarters · filed 2023-05-11 | $1.80M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $459.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $893.00K derived: sum of 2 quarters · filed 2023-03-29 | $1.33M derived: sum of 3 quarters · filed 2023-03-29 | $1.76M 10-K · filed 2023-03-29 |
| 2021-09-30 | $434.00K 10-Q · filed 2022-11-14 | $868.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.30M 10-Q · filed 2022-11-14 | $1.74M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $434.00K 10-Q · filed 2022-08-11 | $868.00K 10-Q · filed 2022-08-11 | $1.30M derived: sum of 3 quarters · filed 2022-08-11 | $1.74M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $434.00K 10-Q · filed 2022-05-13 | $868.00K derived: sum of 2 quarters · filed 2022-05-13 | $1.30M derived: sum of 3 quarters · filed 2022-05-13 | $1.74M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $868.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.30M derived: sum of 3 quarters · filed 2022-03-31 | $1.74M 10-K · filed 2022-03-31 |
| 2020-09-30 | $434.00K 10-Q · filed 2021-11-15 | $868.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.30M 10-Q · filed 2021-11-15 | $1.74M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $434.00K 10-Q · filed 2021-07-28 | $868.00K 10-Q · filed 2021-07-28 | $1.30M derived: sum of 3 quarters · filed 2021-07-28 | $1.74M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $434.00K 10-Q · filed 2021-05-17 | $868.00K derived: sum of 2 quarters · filed 2021-05-17 | $1.30M derived: sum of 3 quarters · filed 2021-05-17 | $1.74M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $868.00K derived: sum of 2 quarters · filed 2021-03-24 | $1.30M derived: sum of 3 quarters · filed 2021-03-24 | $1.59M 10-K · filed 2021-03-24 |
| 2019-09-30 | $434.00K 10-Q · filed 2020-11-09 | $868.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.16M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $434.00K 10-Q · filed 2020-08-10 | $723.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $289.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |